Association of functionally important polymorphisms in cytochrome P450s with squamous cell carcinoma of head and neck

Indian Journal of Experimental Biology

Volumn 48, Issue 7, 2010, Pages 651-665

  Ruwali, Munidra ^a   Parmar, Devendra ^a  

^a CSIR INDIAN INSTITUTE OF TOXICOLOGY RESEARCH   (India)

Author keywords

Alcohol; Carcinoma; Cytochrome P450; Environmental risk factors; Glutathione s transferases; Polymorphism; Tobacco

Indexed keywords

CYTOCHROME P450;

GENETIC POLYMORPHISM; GENETICS; HEAD AND NECK TUMOR; HUMAN; PATHOLOGY; PROGNOSIS; REVIEW; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; CYTOCHROME P-450 ENZYME SYSTEM; HEAD AND NECK NEOPLASMS; HUMANS; POLYMORPHISM, GENETIC; PROGNOSIS;

NICOTIANA TABACUM;

EID: 77954340965     PISSN: 00195189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (118)

1. Parkin D M, Pisani P, Ferlay J, Estimates of the worldwide mortality from eighteen major cancers in 1985, Implications for prevention and projections of future burden, Int J Cancer, 54 (1993) 594.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J Thun M J, Cancer statistics, 2009, CA Cancer J Clin, 59 (1999) 225.
3. Parkin D M, Pisani P Ferlay J, Estimates of the worldwide incidence of 25 major cancers in 1990, Int J Cancer, 80 (1999) 827.
4. Viswanathan H Wilson J A, Alcohol, the neglected risk factor in head and neck cancer, Clin Otolaryngol Allied Sci, 29 (2004) 295.
5. Sankaranarayanan R, Masuyer E, Swaminathan R, Ferlay J & Whelan S, Head and neck cancer: a global perspective on epidemiology and prognosis, Anticancer Res, 18 (1998) 4779.
6. La Vecchia C, Tavani A, Franceschi S, Levi F, Corrao G & Negri E, Epidemiology and prevention of oral cancer, Oral Oncol, 33 (1997) 302.
7. Parkin D M, Whelan S L, Ferlay J et al., Cancer incidence in five continents Vol VII, IARC Scientific Publications No 143. (1997) Lyon: ARC.
8. Tuli B S, Gupta K K Dugg M S, Retrospective and prospective study of head and neck cancer, Indian J Otolaryngology and Head and Neck Surgery, 55 (2003) 11.
9. Brennan P Boffetta P, Mechanistic considerations in the molecular epidemiology of head and neck cancer, IARC Sci Publ 157 (2004) 393.
10. Tomatis L, IARC. Cancer: Causes, Occurrence and Control. (Ed.). IARC Scientific Publications 100, Lyon, 1990.
11. Huang M F, Lin W L & Ma Y C, A study of reactive oxygen species in mainstream of cigarette, Indoor Air, 15 (2005)135.
12. Hecht S S, Tobacco smoke carcinogens and lung cancer, J. Natl Cancer Inst, 91 (1999) 1194.
13. Nair U J, Nair J, Mathew B & Bartsch H, Glutathione S-transferase Ml and Tl null genotypes as risk factors for oral leukoplakia in ethnic Indian betel quid/tobacco chewers, Carcinogenesis, 20 (1999) 743.
14. Hsu T, Furlong C Spitz M R &Ethyl alcohol as a cocarcinogen with special reference to the aerodigestive tract: a cytogenetic study, Anticancer Res, 11 (1991)1097.
15. Schlecht N F, Franco E L, Pintos J, Negassa A, Kowalski L P, Oliveira B V & Curado M P, Interaction between tobacco and alcohol consumption and the risk of cancers of the upper aero-digestive tract in Brazil, Am J Epidemiol, 150 (1999)1129.
16. Bartsch H, Nair U, Risch A, Rojas M, Wikman H & Alexandrov K, Genetic polymorphisms of CYP gene, alone or in combination as a risk modifier of tobacco related cancers, Cancer Epidemiol Biomarker Prev, 9 (2000) 3.
17. Singh A P, Shah P P, Ruwali M, Mathur N, Pant M C, & Parmar D, Polymorphism in cytochrome P4501A1 is significantly associated with head and neck cancer risk, Cancer Invest, 27 (2009) 869.
18. Singh A P, Shah P P, Mathur N, Buters J T, Pant M C & Parmar D, Genetic polymorphisms in cytochrome P4501B1 and susceptibility to head and neck cancer, Mutat Res, 639 (2008)11.
19. Ruwali M, Khan A J, Shah P P, Singh A P, Pant M C & Parmar D, Cytochrome P450 2E1 and head and neck cancer: interaction with genetic and environmental risk factors, Environ Mol Mutagen, 50 (2009) 473.
20. Oyama T, Mitsudomi T, Kawamoto T, Ogami A, Osaki T, Kodama Y & Yasumoto K, Detection of CYP1A1 gene polymorphism using designed RFLP and distributions of CYP1A1 genotypes in Japanese, Int Arch Occup Environ Health, 67 (1995) 253.
21. Sato M, Sato T, Izumo T & Amagasa T, Genetic polymorphism of drug-metabolizing enzymes and susceptibility to oral cancer, Carcinogenesis, 20 (1999) 1927.
22. Garte S, Gaspari L, Alexandrie A K, Ambrosone C, Autrup H, Autrup J L, Baranova H, Bathum L, Benhamou S, Boffetta P, Bouchardy C, Breskvar K, BrockmoUer J, Cascorbi I, Clapper M L, Coutelle C, Daly A, Dell'Omo M, Dolzan V, Dresler C M, Fryer A, Haugen A, Hein D W, Hildesheim A, Hirvonen A, Hsieh L L, Ingelman-Sundberg M, Kalina I, Kang D, Kihara M, Kiyohara C, Kremers P, Lazarus P, Le Marchand L, Lechner M C, van Lieshout E M, London S, Manni J J, Maugard C M, Morita S, Nazar-Stewart V, Noda K, Oda Y, Parl F F, Pastorelli R, Persson I, Peters W H, Rannug A, Rebbeck T, Risch A, Roelandt L, Romkes M, Ryberg D, Salagovic J, Schoket B, Seidegard J, Shields P G, Sim E, Sinnet D, Strange R C, Stucker I, Sugimura H, To-Figueras J, Vineis P, Yu M C & Taioli E, Metabolic gene polymorphism frequencies in control populations, Cancer Epidemiol Biomarkers Prev 10 (2001) 1239.
23. Cascorbi I, Brockmoeller J & Roots I, A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility, Cancer Res, 56 (1996) 4965.
24. Hayashi S, Watanabe J & Kawajiri K, High susceptibility to lung cancer analyzed in terms of combined genotypes of P4501A1 and Mu-class glutathione-S-transferase genes, Jpn J Cancer Res, 83 (1992) 866-870.
25. Hirvonen A, Husgafvel-Pursiainen K, Karjalainen A, Anttila S & Vainio H, Point mutational Mspl and Ile-Val polymorphisms closely linked in the CYP1A1 gene: lack of association with susceptibility to lung cancer in a Finnish study population, Cancer Epidemiol Biomark Prev 1 (1992)485.
26. Kawajiri K, Nakachi K, Imai K, Yoshii A, Shinoda N & Watanabe J, Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P450IA1 gene, FEBS Lett, 263 (1990) 131.
27. Shah P P, Saurabh K, Pant M C, Mathur N & Parmar D, Evidence for increased cytochrome P450 1A1 expression in blood lymphocytes of lung cancer patients, Mutat Res, 670 (2009) 74.
28. Sasaki M, Tanaka Y, Kaneuchi M, Sakuragi N & Dahiya R, Alleles of polymorphic sites that correspond to hyperactive variants of CYP1B1 protein are significantly less frequent in Japanese as compared to American and German populations, Hum Mutat, 21 (2003) 652.
29. Long J R, Shu X O, Cai Q, Cai H, Gao Y T, Jin F & Zheng W, Polymorphisms of the CYP1B1 gene may be associated with the onset of natural menopause in Chinese women, Maturitas, 55(2006)238.
30. Aklillu E, Oscarson M, Hidestrand M, Leidvik B, Otter C & Ingelman- Sundberg M, Functional analysis of six different polymorphic CYP1B1 enzyme variants found in an Ethiopian population, Molecular Pharmacol, 63 (2002) 586.
31. Shimada T, Watanabe J, Kawajiri K, Sutter T R, Guengerich F P, Gillam E M & Inoue K, Catalytic properties of polymorphic human cytochrome P450 1B1 variants, Carcinogenesis, 20 (1999) 1607.
32. Indian Genome Variation Consortium, Genetic landscape of the people of India: A canvas for disease gene exploration,/Genet, 87 (2008) 3.
33. Kato S, Shields P G, Caporaso N E, Hoover R N, Trump B F, Sugimura H, Weston A & Harris C C, Cytochrome P450IIE1 polymorphisms, racial variation and lung cancer risk, Cancer Res, 52(1993)6712.
34. Savolainen V T, Pajarinen J, Perola M, Penttila A & Karhunen P J, Polymorphism in the cytochrome P4502E1 gene and risk of alcoholic liver disease,/Hepatol, 26 (1997) 55.
35. Mc Carver D G, Byun R, Hines R N, Hichme M & Wegenek W, A genetic polymorphism in the regulatory sequences of human CYP2E1: association with increased chlorzoxazone hydroxylation in the presence of obesity and ethanol intake, ToxicolAppl Pharmacol, 152 (1998) 276.
36. Vidal F, Lorenzo A, Auguet T, Olona M, Broch M, Gutierrez C, Aguilar C, Estupina P, Santos M & Richart C, Genetic polymorphisms of ADH2, ADH3, CYP4502E1 Dra-I and Pst-I, and ALDH2 in Spanish men: lack of association with alcoholism and alcoholic liver disease,/Hepatol, 41 (2004) 744.
37. Tanaka F, Shiratori Y, Yokosuka O, Imazeki F, Tsukada Y & Omata M, Polymorphism of alcohol-metabolizing genes affects drinking behavior and alcoholic liver disease in Japanese men, Alcohol: Clinical and Experimental Research, 21 (1997)596.
38. Hu Y, Hakkola J, Oscarson M & Ingelman-Sundberg M, Structural and functional characterization of the 5'-flanking region of the rat and human cytochrome P450 2E1 genes: identification of a polymorphic repeat in the human gene, Biochem Biophys Res Commun, 263 (1999) 286.
39. Mittal R D, Srivastava D S, Mandhani A & Mittal B, Genetic Polymorphism of Drug Metabolizing Enzymes (CYP2E1, GSTP1) and Susceptibility to Bladder Cancer in North India, Asian Pac J Cancer Prev, 6 (2005) 6.
40. Soya S S, Padmaja N & Adithan C, Genetic Polymorphism of CYP2E1 and GSTP1 in a South Indian Population-Comparisons with North India, Caucasians and Chinese, Asian Pac J Cancer Prev, 6 (2005) 315.
41. Stephens E A, Taylor J A, Kaplan N, Yang C H, Hsieh L L, Lucier G W & Bell D A, Ethnic variation in the CYP2E1 gene: polymorphism analysis of 695 African-Americans, European-Americans and Taiwanese, Pharmacogenetics, 4 (1994)185.
42. Grove J, Brown A S, Daly A K, Bassendine M F, James O F & Day C P, The Rsal polymorphism of CYP2E1 and susceptibility to alcoholic liver disease in Caucasians: effect on age of presentation and dependence on alcohol dehydrogenase genotype, Pharmacogenetics, 8 (1998) 335.
43. Wong N A C S, Rae F, Simpson K J, Murray G D & Harrison D J Genetic polymorphism of cytochrome P4502E1 and susceptibility to alcoholic liver disease and hepatocellular carcinoma in a white population: a study and literature review, including meta-analysis, Journal of Clinical Pathology/Molecular Pathology, 53 (2000) 88.
44. Hildesheim A, Anderson L M, Chen C J, Cheng Y J, Brinton L A, Daly A K, Reed C D, Chen I H, Caporaso N E & Hsu M M, CYP2E1 genetic polymorphisms and risk of nasopharyngeal carcinoma in Taiwan, J Nad Cancer Inst, 89 (1997) 1207.
45. Chao Y C, Young T H, Tang H S & Hsu C T, Alcoholism and alcoholic organ damage and genetic polymorphisms of alcohol metabolizing enzymes in Chinese patients, Hepatology, 25 (1997) 112.
46. Xu C, Goodz S, Sellers E M & Tyndale R F, CYP2A6 genetic variation and potential consequences, Adv Drug Deliv Rev, 54 (2002) 1245.
47. Ruwali M, Pant M C, Shah P P, Mishra B N & Parmar D, Polymorphism in cytochrome P450 2A6 and glutathione S-transferase PI modifies head and neck cancer risk and treatment outcome, Mutat Res, 669 (2009) 36.
48. Topcu Z, Chiba I, Fujieda M, Shibata T, Ariyoshi N, Yamazaki H & Sevgican F, Muthumala M, Kobayashi H, Kamataki T, CYP2A6 gene deletion reduces oral cancer risk in betel quid chewers in Sri Lanka, Carcinogenesis, 23 (2002)595.
49. Tiwawech D, Srivatanakul P, Karalak A & Ishida T, Cytochrome P450 2A6 polymorphism in nasopharyngeal carcinoma, Cancer Lett, 241 (2006) 135.
50. Ko Y, Abel J, Harm V, Brode P, Antony C, Donat S, Fischer H P, Ortiz-Pallardo M E, Thier R, Sachinidis A, Vetter H, Bolt H M, Herberhold C & Bruning T, Association of CYP1B1 codon 432 mutant allele in head and neck squamous cell cancer is reflected by somatic mutations of p53 in tumor tissue, Cancer Res, 61 (2001) 4398.
51. Ho T, Wei Q & Sturgis E M, Epidemiology of carcinogen metabolism genes and risk of squamous cell carcinoma of the head and neck, Head Neck, 29 (2007) 682.
52. Danko I M & Chaschin N A, Association of CYP2E1 gene polymorphism with predisposition to cancer development, Exp Oncol, 272 (2005) 248.
53. Boccia S, Cadoni G, Sayed-Tabatabaei F A, Volante M, Arzani D, De Lauretis A, Cattel C, Almadori G & van Duijn C M, Paludetti G, Ricciardi G, CYP1A1, CYP2E1, GSTM1, GSTT1, EPHX1 exons 3 and 4, and NAT2 polymorphisms, smoking, consumption of alcohol and fruit and vegetables and risk of head and neck cancer, J Cancer Res Clin Oncol, 134 (2008) 93.
54. Harth V, Schafer M, Abel J, Maintz L, Neuhaus T, Besuden M, Primke R, Wilkesmann A, Thier R, Vetter H, Ko Y D, Bruning T, Bolt H M & Ickstadt K, Head and neck squamous-cell cancer and its association with polymorphic enzymes of xenobiotic metabolism and repair, J Toxicol Environ Health, 71 (2008) 887.
55. Tanimoto K, Hayashi S, Yoshiga K & Ichikawa T, Polymorphisms of the CYP1A1 and GSTM1 gene involved in oral squamous cell carcinoma in association with a cigarette dose, Oral Oncol, 35 (1999) 191.
56. Cha I H, Park J Y, Chung W Y, Choi M A, Kim H J & Park K K, Polymorphisms of CYP1A1 and GSTM1 genes and susceptibility to oral cancer, Yonsei Med J, 48 (2007) 233.
57. Park J Y, Muscat J E, Ren Q, Schantz S P, Harwick R D, Stern J C, Pike V, Richie J P & Lazarus P, CYP1A1 and GSTM1 polymorphisms and oral cancer risk, Cancer Epidemiol Biomarkers Prev, 6 (1997) 791.
58. Morita S, Yano M, Tsujinaka T, Akiyama Y, Taniguchi M, Kaneko K, Miki H, Fujii T, Yoshino K, Kusuoka H & Monden M, Genetic polymorphisms of drug-metabolizing enzymes and susceptibility to head-and-neck squamous-cell carcinoma, Int J Cancer, 80 (1999) 685.
59. Sato M, Sato T, Izumo T & Amagasa T, Genetically high susceptibility to oral squamous cell carcinoma in terms of combined genotyping of CYP1A1 and GSTM1 genes, Oral Oncol, 36 (2000) 267.
60. Oude Ophuis M B, van Lieshout E M, Roelofs H M, Peters W H & Manni J J, Glutathione-S-transferase Ml and Tl and cytochrome P4501A1 polymorphisms in relation to the risk for benign and malignant head and neck lesions, Cancer, 82 (1998)936.
61. Gajecka M, Rydzanicz M, Jaskula-Sztul R, Kujawski M, Szyfter W & Szyfter K, CYP1A1, CYP2D6, CYP2E1, NAT2, GSTM1 and GSTT1 polymorphisms or their combinations are associated with the increased risk of the laryngeal squamous cell carcinoma, Mutat Res, 574 (2005) 112.
62. Hashibe M, Brennan P, Strange R C, Bhisey R, Cascorbil I, Lazarus P, Oude Ophuis M B, Benhamou S, Foulkes W D, Katoh T, Coutelle C, Romkes M, Gaspari L, Taioli E & Boffetta P, Meta- and pooled analyses of GSTM1, GSTT1, GSTP1, and CYP1A1 genotypes and risk of head and neck cancer, Cancer Epidemiol Biomarkers Prev, 12 (2003) 1509.
63. Jaworowska E, Masojc B, Tarnowska C, Brzosko M, Flicinski J, Serrano-Fernandez P, Matyjasik J, Amernik K, Scott R J & Lubinski J, Association between early-onset breast and laryngeal cancers, Breast Cancer Res Treat, 97 (2006)215.
64. Li G, Liu Z, Sturgis E M, Chamberlain R M, Spitz M R & Wei Q, CYP2E1 G1532C, NQOl Prol87Ser, and CYP1B1 Val432Leu polymorphisms are not associated with risk of squamous cell carcinoma of the head and neck, Cancer Epidemiol Biomarkers Prev, 14 (2005) 1334.
65. Hildesheim A, Chen C J, Caporaso N E, Cheng Y J, Hoover R N, Hsu M M, Levine P H, Chen I H, Chen J Y, Yang C S, Daly A K & Idle J R, Cytochrome P4502E1 genetic polymorphisms and risk of nasopharyngeal carcinoma: Results from a case-control study conducted in Taiwan, Cancer Epidemiol Biomarkers Prev, 4 (1995) 607.
66. Hung HC, Chuang J, Chien Y C, Chern H D, Chiang C P, Kuo Y S, Chen A & Hildesheim C J, Genetic polymorphisms of CYP2E1, GSTM1, and GSTT1; environmental factors and risk of oral cancer, Cancer Epidemiol Biomarkers Prev, 6 (1997)901.
67. Kongruttanachok N, Sukdikul S, Setavarin S, Kerekhjanarong V, Supiyaphun P, Voravud N, Poovorawan Y & Mutirangura A, Cytochrome P450 2E1 polymorphism and nasopharyngeal carcinoma development in Thailand: A correlative study, BMC Cancer, 1 (2001) 4. 664
68. Sugimura T, Kumimoto H, Tohnai I, Fukui T, Matsuo K, Tsurusako S, Mitsudo K, Ueda M, Tajima K & Ishizaki K, Gene-environment interaction involved in oral carcinogenesis: Molecular epidemiological study for 81 metabolic and DNA repair gene polymorphisms, J Oral PatholMed, 35(2006)11.
69. Bouchardy C, Hirvonen A, Coutelle C, Patrick J, Pierre D & Benhamou S, Role of alcohol dehydrogenase 3 and 82 Cytochrome P-4502E1 genotypes in susceptibility to cancers of the upper aerodigestive tract, Int J Cancer, 87 (2000) 734.
70. Soya S S, Vinod T, Reddy K S, Gopalakrishnan S & Adithan C, CYP2E1 polymorphisms and gene-environment interactions in the risk of upper aerodigestive tract cancers among Indians, Pharmacogenomics, 9 (2008) 551.
71. Landi M T, Bergen A W, Baccarelli A, Patterson D G Jr, Grassman J, Ter-Minassian M, Mocarelli P, Caporaso N, Masten S A, Pesatori A C, Pittman G S & Bell D A, CYP1A1 and CYP1B1 genotypes, haplotypes, and TCDD- induced gene expression in subjects from Seveso, Italy, Toxicology, 207(2005) 191.
72. Chakrabarti S, Kaur K, Kaur I, Mandal A K, Parikh R S, Thomas R & Majumder P P, Globally, CYP1B1 mutations in primary congenital glaucoma are strongly structured by 84 geographic and haplotype backgrounds, Invest Ophthalmol Vis Sci 41 (2006)43.
73. Yang M, Tsuang J & Wan Y J Y, A haplotype analysis of CYP2E1 polymorphisms in relation to alcoholic phenotypes 85 in Mexican Americans, Alcohol Clin Exp Res, 31 (2007) 1991.
74. Lee M Y, Mukherjee N, Pakstis A J, Khaliq S, Mohyuddin A, Mehdi S Q, Speed W C, Kidd J R & Kidd K K, Global patterns of variation in allele and haplotype frequencies and 86 linkage disequilibrium across the CYP2E1 gene, Pharmacogenomics J, 8 (2008) 349.
75. Yadav S S, Ruwali M, Shah P P, Mathur N, Singh R L, Pant M C & Parmar D, Association of poor metabolizers of 87 cytochrome P450 2C19 with head and neck cancer and poor treatment response, Mutat Res, 644 (2008) 31.
76. Yadav S S, Ruwali M, Pant M C, Shukla P, Singh R L & Parmar D, Interaction of drug metabolizing cytochrome P450 2D6 poor metabolizers with cytochrome P450 2C9 and 2C19 88 genotypes modify the susceptibility to head and neck cancer and treatment response, Mutat Res, 684 (2010) 49.
77. Fujita K & Kamataki T, Predicting the mutagenicity of tobacco-related N-nitrosamines in humans using 11 strains of Salmonella typhimurium YG7108, each coexpressing a form 89 of human cytochrome P450 along with NADPH-cytochrome P450 reductase, Environ Mol Mutagen, 38 (2001) 339.
78. Fujita K & Kamataki T, Role of human cytochrome P450 (CYP) in the metabolic activation of N-alkylnitrosamines: application of genetically engineered Salmonella 90 typhimurium YG7108 expressing each form of CYP together with human NADPH-cytochrome P450 reductase, Mutat Res, 483 (2001) 35.
79. Yamazaki Y, Fujita K, Nakayama K, Suzuki A, Nakamura K, Yamazaki H & Kamataki T, Establishment of ten strains 91 of genetically engineered Salmonella typhimurium TA1538 each co-expressing a form of human cytochrome P450 with NADPH-cytochrome P450 reductase sensitive to various promutagens, Mutat Res, 562 (2004) 151.
80. Sugimoto M, Furuta T, Shirai N, Kajimura M, Hishida A, Sakurai M, Ohashi K & Ishizaki T, Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status, Clin Pharmacol Ther, 76 (2004) 290.
81. London S J, Sullivan-Klose T, Daly A K & Idle J R, Lung cancer risk in relation to the CYP2C9 genetic polymorphism among Caucasians in Los Angeles County, Pharmacogenetics, 7 (1997) 401.
82. Matthias C, Bockmuhl U, Jahnke V, Jones P W, Hayes J D, Alldersea J, Gilford J, Bailey L, Bath J, Worrall S F, Hand P, Fryer A A & Strange R C, Polymorphism in cytochrome P450 CYP2D6, CYP1A1, CYP2E1 and glutathione S-transferase, GSTM1, GSTM3, GSTT1 and susceptibility to tobacco-related cancers: studies in upper aerodigestive tract cancers, Pharmacogenetics, 8 (1998) 91.
83. Matthias C, Jahnke V, Jones P W, Hoban P R, Alldersea J E, Worrall S F, Fryer A A & Strange R C, Cyclin Dl, glutathione S-transferase, and cytochrome P450 genotypes and outcome in patients with upper aerodigestive tract cancers: assessment of the importance of individual genes using multivariate analysis, Cancer Epidemiol Biomarkers Prev, 8 (1999) 815.
84. Gronau S, Koenig-Greger D, Jerg M & Riechelmann H, Gene polymorphisms in detoxification enzymes as susceptibility factor for head and neck cancer?, Otolaryngol Head Neck Surg, 128 (2003) 674.
85. Agundez JAG, Gallardoa L, Ledesma M C, Lozano L, Rodriguez-Lescure A, Pontes J C, Iglesias-Moreno M C, Poch J, Ladero J M & Benitez J, Functionally active duplications of the CYP2D6 gene are more prevalent among larynx and lung cancer patients, Oncology, 61 (2001) 59.
86. Rostami-Hodjegan A, Lennard M S, Woods H F & Tucker G T, Metaanalysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinson's disease, Pharmacogenetics, 8 (1998) 227.
87. Laforest L, Wikman H, Benhamou S, Saarikoski S T, Bouchardy C, Hirvonen A, Dayer P & Husgafvel-Pursiainen K, CYP2D6 gene polymorphism in Caucasian smokers: lung cancer susceptibility and phenotype-genotype relationships, EurJ Cancer, 36 (2000) 1825.
88. Li H, Feng L, Xu Y, Yao L, Ouyang T, Li J, Wang T, Fan Z, Lin B, Li J & Xie Y, The association of CYP2D610 polymorphism with breast cancer risk and clinico-pathologic characteristics in Chinese women, Ada Oncol, 45 (2006) 597.
89. Chan A T, Tranah G J, Giovannucci E L, Hunter D J & Fuchs C S, A prospective study of genetic polymorphisms in the cytochrome P-450 2C9 enzyme and the risk for distal colorectal adenoma, Clin Gastroenterol Hepatol, 2 (2004) 704.
90. Tranah G J, Andrew T C, Giovannucci E, Ma J, Fuchs C & Hunter D J, Epoxide hydrolase and CYP2C9 polymorphisms, cigarette smoking, and risk of colorectal carcinoma in the nurses' health study and the physicians' health study, Mol Carcinogen, 44(2005)21.
91. Wolf R C, Smith CAD, Gough A C, Moss J E, Vallis K A, Howard G, Carey F J, Mills K, McNee W, Carmichael J & Spurr N K, Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility, Carcinogenesis, 13 (1992) 1035.
92. Roddam P L, Rollinson S, Kane E, Roman E, Moorman A, Cartwright R & Morgan G J, Poor metabolizers at the cytochrome P450 2D6 and 2C19 loci are at increased risk of developing adult acute leukaemia, Pharmacogenetics, 10 (2000)605.
93. Hayes J D & Strange R C, Glutathione S-transferase polymorphisms and their biological consequences, Pharmacology, 61 (2000) 154.
94. Geisler S A & Olshan A F, GSTM1, GSTT1 and the risk of 108 squamous cell carcinoma of the head and neck: a mini-review, Am J Epidemiol, 154 (2001) 95.
95. Oude Ophuis M B, Roelofs H M J, van den Brandt P A, Peters W H M & Manni J J, Polymorphisms of the glutathione-S-transferase PI gene and head and neck cancer 109 susceptibility, Head Neck, 25 (2003) 37.
96. Singh M, Shah P P, Singh A P, Ruwali M, Mathur N, Pant M C & Parmar D, Association of genetic polymorphisms in glutathione S-transferases and susceptibility to head and neck 110 cancer, MutatRes, 638 (2008)184.
97. Sreelekha T T, Ramadas K, Pandey M, Thomas G, Nalinakumari K R & Pillai M R, Genetic polymorphism of CYP1A1, GSTM1 and GSTT1 genes in Indian oral cancer, 111 Oral Oncol, 37(2001)593.
98. Buch S C, Notani P N & Bhisey R A, Polymorphism at GSTM1, GSTM3 and GSTT1 gene loci and susceptibility to oral cancer in an Indian population, Carcinogenesis, 23 112 (2002) 803.
99. Soya S S, Vinod T, Reddy K S, Gopalakrishnan S & Adithan C, Genetic polymorphisms of glutathione-S-transferase genes (GSTM1, GSTT1 and GST PI) and upper aerodigestive tract cancer risk among smokers, tobacco chewers and alcoholics 113 in an Indian population, Eur J Cancer, 43 (2007) 2698.
100. Anantharaman D, Chaubal P M, Kannan S, Bhisey R A & Mahimkar M B, Susceptibility to oral cancer by genetic polymorphisms at CYP1A1, GSTM1 and GSTT1 loci among Indians: tobacco exposure as a risk modulator, Carcinogenesis, 28 (2007) 1455.
101. Hiyama T, Yoshihara M, Tanaka S & Chayama K, Genetic polymorphisms and head and neck cancer risk (Review), Int J Oncol, 32(2008)945.
102. Tripathy C B & Roy N, Meta-analysis of glutathione S- 115 transferase Ml genotype and risk toward head and neck cancer, Head Neck, 28 (2006) 217.
103. Hu X, Xia H, Srivastava S K, Herzog C, Awasthi Y C, Ji X, Zimniak P & Singh S V, Activity of four allelic forms of glutathione-S-transferase hGSTP-1 for epoxides of 116 polycyclic aromatic hydrocarbons, Biochem Biophys Res Commun, 238 (1997) 397.
104. Saarikoski S T, Voho A, Reinikainen M, Anttila S, Karjalainen A, Malaveille C, Vainio H, Husgafvel- Pursiainen K & Hirvonen A, Combined effect of polymorphic GST genes on individual susceptibility to lung cancer, Int J Cancer, 11 (1998) 516.
105. Rothman K & Keller A, The effect of joint exposure to alcohol and tobacco on risk of cancer of the mouth and 118 pharynx,/Chronic Dis, 25 (1972) 711.
106. Blot W J, McLaughlin J K, Winn D M, Austin D F, Greenberg R S, Preston-Martin S, Bernstein L, Schoenberg J B, Stemhagen A & Fraumeni J F Jr, Smoking and drinking in relation to oral and pharyngeal cancer, Cancer Res, 48 (1988)3282.
107. Tanimoto K, Hayashi S, Yoshiga K & Ichikawa T, Polymorphisms of the CYP1A1 and GSTM1 gene involved in oral squamous cell carcinoma in association with a cigarette dose, Oral Oncol, 35 (1999) 191.
108. Sugimoto M, Furuta T, Shirai N, Nakamura A, Kajimura M, Sugimura H, Hishida A & Ishizaki T, Poor metabolizer genotype status of CYP2C19 is a risk factor for developing gastric cancer in Japanese patients with Helicobacter pylori infection, Aliment Pharmacol Ther, 22 (2005) 1033.
109. Ouerhani S, Marrakchi R, Bouhaha R, Slama M R B, Sfaxi M & Ayed M, Chebil M, Gaaied A B A E, The role of CYP2D64 variant in bladder cancer susceptibility in Tunisian patients, Bull Cancer, 95 (2008) 1
110. Kato S, Bowman E D, Harrington A M, Blomeke B & Shields P G, Human lung carcinogen-DNA adduct levels mediated by genetic polymorphisms in vivo, J Natl Cancer Inst, 87 (1995) 902.
111. Caporaso N E, Lerman C, Audrain J, Boyd N R, Main D, Issaq H J, Utermahlan B, Falk R T & Shields P, Nicotine metabolism and CYP2D6 phenotype in smokers, Cancer Epidemiol Biomarkers Prev, 10 (2001) 261.
112. Ariyoshi N, Miyamoto M, Umetsu Y, Kunitoh H, Dosaka-Akita H, Sawamura Y, Yokota J, Nemoto N, Sato K & Kamataki T, Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers, Cancer Epidemiol Biomarkers Prev, 11 (2002)890.
113. Fujieda M, Yamazaki H, Saito T, Kiyotani K, Gyamfi M A, Sakurai M, Dosaka- Akita H, Sawamura Y, Yokota J, Kunitoh H & Kamataki T, Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco related lung cancer risk in male Japanese smokers, Carcinogenesis, 12 (2004) 2451.
114. Munafo M R, Clark T G, Johnstone E C, Murphy M F G & Walton R T, The genetic basis for smoking behavior: a systematic review and meta-analysis, Nicotine Tob Res, 6 (2004)583.
115. Hamel N, Karimi S, Hebert-Blouin M N, Brunet J S, Gilfix B, Ghadirian P, Black M J, Narod S A & Foulkes W D, Increased risk of head and neck cancer in association with GSTT1 nullizygosity for individuals with low exposure to tobacco, Int J Cancer, 87 (2000) 452.
116. Kihara M, Kihara M, Kubota A, Furukawa M & Kimura H, GSTM1 gene polymorphism as a possible marker for susceptibility to head and neck cancers among Japanese smokers, Cancer Lett, 112 (1997) 257.
117. Jourenkova N, Reinikainen M, Bouchardy C, Dayer P, Benhamou S & Hirvonen A, Larynx Cancer Risk in Relation to Glutathione S-Transferase Ml and Tl Genotypes and Tobacco Smoking, Cancer Epidem Biomarkers Prev, 1 (1998) 19.
118. Peters E S, McClean M D, Marsit C J, Luckett B & Kelsey K T, Glutathione S-transferase polymorphisms and the synergy of alcohol and tobacco in oral, pharyngeal, and laryngeal carcinoma, Cancer Epidemiol Biomarkers Prev, 15 (2006) 2196.